Sudden sensorineural hearing loss (SSNHL) is a perplexing medical condition characterized by rapid hearing decline, often accompanied by symptoms such as tinnitus and vertigo. Effectiveness of batroxobin treatment is not clearly known. OBJECTIVE: To systematically review and meta-synthesize the effectiveness of Batroxobin treatment on SSNHL.
✦ The floor
Discussion
Signed responses from readers of the wire.
This meta-analysis provides the strongest available evidence to date on defibrinogenation therapy for sudden sensorineural hearing loss; audiologists should be aware of findings when coordinating care with ENT/otology colleagues, though prescribing decisions remain with medical physicians.
Sudden sensorineural hearing loss has limited proven treatments, and a meta-analysis on defibrinogenation therapy could meaningfully inform otolaryngology and audiology collaborative care pathways.
- 01Systematic review and meta-analysis pooling evidence on defibrinogenation therapy (blood-thinning treatment targeting fibrinogen) for sudden hearing loss.
- 02Sudden sensorineural hearing loss (SSNHL) is a rapid, unexplained loss of hearing in one or both ears — a medical emergency.
- 03Meta-analyses provide the highest level of evidence outside of individual large RCTs.
- 04Published in Laryngoscope Investigative Otolaryngology (2026).
- 05Specific effect sizes and number of included studies not available from the provided description.
Defibrinogenation therapy is efficacious for the treatment of sudden sensorineural hearing loss.
studypartially supported- PMID
- 42871297
- DOI
- 10.1002/lio2.70599.
- Journal
- Laryngoscope Investigative Otolaryngology
- Publication type
- meta_analysis
- Evidence level
- 1a
- Population
- Patients with sudden sensorineural hearing loss
- Intervention
- Defibrinogenation therapy (fibrinogen-depleting agent to improve inner ear blood flow)
Primary outcomes
Hearing recovery outcomes following defibrinogenation therapy for SSNHL